Sökning: WFRF:(Sederholm T)
> (2010-2014) >
A randomised phase ...
A randomised phase II study of pemetrexed versus pemetrexed plus erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
-
- Dittrich, Christian (författare)
- Kaiser Franz Josef Spital, Austria Kaiser Franz Josef Spital, Austria
-
- Papai-Szekely, Zsolt (författare)
- St George Hospital Fejer County, Hungary
-
- Vinolas, Nuria (författare)
- Hospital Clin Barcelona, Spain
-
visa fler...
-
- Sederholm, Christer (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Lungmedicinska kliniken US
-
- Hartmann, Joerg T. (författare)
- Department Internal Medical II Hematol and Medical Oncol, Germany Catholic Hospital Consortium Ostwestfalen, Germany
-
- Behringer, Dirk (författare)
- Clin Hematol and Oncol, Germany
-
- Kazeem, Gbenga (författare)
- Eli Lilly UK, England
-
- Desaiah, Durisala (författare)
- Eli Lilly Corp Centre, IN USA
-
- Leschinger, Monika I. (författare)
- Lilly Deutschland GmbH, Germany
-
- von Pawel, Joachim (författare)
- Asklepios Hospital Munchen Gauting, Germany
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2014
- 2014
- Engelska.
-
Ingår i: European Journal of Cancer. - : Elsevier. - 0959-8049 .- 1879-0852. ; 50:9, s. 1571-1580
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed + erlotinib in patients with advanced non-squamous NSCLC. Methods: NSCLC stage III-IV patients who failed one prior platinum-based chemotherapy regimen, greater than= 1 measurable lesion by Response Evaluation Criteria in Solid Tumors, and Eastern Cooperative Oncology Group performance status less than= 2 were eligible. Patients received pemetrexed 500 mg/m(2) with vitamin B-12 and folic acid q3w alone or combined with erlotinib 150 mg daily. The primary end-point was progression-free survival (PFS). Secondary end-points were overall survival (OS), time-to-treatment failure (TTTF), response and toxicity. Results: Of 165 randomised non-squamous patients, 159 were treated (pemetrexed: 83; pemetrexed + erlotinib: 76). The median PFS (months; 95% CI) was 2.89 (1.94, 3.38) for pemetrexed versus 3.19 (2.86, 4.70) for pemetrexed + erlotinib (hazard ratio [HR] 0.63; 95% CI: (0.44, 0.90); P = 0.0047). The median OS (months; 95% CI) was 7.75 (5.29, 10.41) for pemetrexed versus 11.83 (8.18, 16.66) for pemetrexed + erlotinib (HR: 0.68; 95% CI: 0.46, 0.98; P = 0.019). The median TTTF (months: 95% CI) was 2.4 (1.74, 2.99) for pemetrexed versus 3.0 (2.23, 4.07) for pemetrexed + erlotinib (HR 0.64; 95% CI: 0.46, 0.89; P = 0.0034). One patient died in pemetrexed + erlotinib arm due to febrile neutropenia. Grades 3/4 drug-related toxicities (in greater than= 5% of patients) in pemetrexed/pemetrexed + erlotinib were febrile neutropenia (2.4%/10.5%), diarrhoea (1.2%/5.3%), rash (1.2%/9.2%); anaemia (6%/11.8%), leukopenia (9.6%/23.7%), neutropenia (9.6%/25.0%), and thrombocytopenia (4.8%/14.5%). Conclusions: Pemetrexed + erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- Non-small cell lung cancer; Non-squamous; Second-line therapy; Pemetrexed; Erlotinib
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Dittrich, Christ ...
-
Papai-Szekely, Z ...
-
Vinolas, Nuria
-
Sederholm, Chris ...
-
Hartmann, Joerg ...
-
Behringer, Dirk
-
visa fler...
-
Kazeem, Gbenga
-
Desaiah, Durisal ...
-
Leschinger, Moni ...
-
von Pawel, Joach ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Linköpings universitet